203 related articles for article (PubMed ID: 15475569)
1. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
Bauman DR; Rudnick SI; Szewczuk LM; Jin Y; Gopishetty S; Penning TM
Mol Pharmacol; 2005 Jan; 67(1):60-8. PubMed ID: 15475569
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
4. The roles of aldo-keto reductases in steroid hormone action.
Bauman DR; Steckelbroeck S; Penning TM
Drug News Perspect; 2004 Nov; 17(9):563-78. PubMed ID: 15645014
[TBL] [Abstract][Full Text] [Related]
5. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Desmond JC; Mountford JC; Drayson MT; Walker EA; Hewison M; Ride JP; Luong QT; Hayden RE; Vanin EF; Bunce CM
Cancer Res; 2003 Jan; 63(2):505-12. PubMed ID: 12543809
[TBL] [Abstract][Full Text] [Related]
6. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
8. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
Shureiqi I; Chen D; Lotan R; Yang P; Newman RA; Fischer SM; Lippman SM
Cancer Res; 2000 Dec; 60(24):6846-50. PubMed ID: 11156377
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
10. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.
Burczynski ME; Lin HK; Penning TM
Cancer Res; 1999 Feb; 59(3):607-14. PubMed ID: 9973208
[TBL] [Abstract][Full Text] [Related]
11. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.
Han S; Inoue H; Flowers LC; Sidell N
Clin Cancer Res; 2003 Oct; 9(12):4627-35. PubMed ID: 14555539
[TBL] [Abstract][Full Text] [Related]
12. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
Lovering AL; Ride JP; Bunce CM; Desmond JC; Cummings SM; White SA
Cancer Res; 2004 Mar; 64(5):1802-10. PubMed ID: 14996743
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic acid.
Chulada PC; Langenbach R
J Pharmacol Exp Ther; 1997 Feb; 280(2):606-13. PubMed ID: 9023270
[TBL] [Abstract][Full Text] [Related]
15. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
Kalgutkar AS; Kozak KR; Crews BC; Hochgesang GP; Marnett LJ
J Med Chem; 1998 Nov; 41(24):4800-18. PubMed ID: 9822550
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
Gobec S; Brozic P; Rizner TL
Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
[TBL] [Abstract][Full Text] [Related]
17. Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells.
Chien CW; Ho IC; Lee TC
Carcinogenesis; 2009 Oct; 30(10):1813-20. PubMed ID: 19696165
[TBL] [Abstract][Full Text] [Related]
18. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
19. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
